Drug Profile
Lutetium-177 satoreotide tetraxetan - Ariceum Therapeutics
Alternative Names: 177Lu-DOTA- JR11; 177Lu-IPN01072; 177Lu SSO 110; 177Lu-IPN-1072; 177Lu-OPS 201; 177Lu-satoreotide; [177Lu]LuSSO110; Lutetium-177-DOTA-satoreotide; SOMther®Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator OctreoPharm Sciences
- Developer Ariceum Therapeutics; Ipsen
- Class Antineoplastics; Drug conjugates; Peptides; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Neuroendocrine tumours
- Phase I Small cell lung cancer
- Phase 0 Meningioma
- Preclinical Merkel cell carcinoma
Most Recent Events
- 28 Sep 2023 Safety and efficacy data from a phase I/II trial in Neuroendocrine tumours released by Ariceum Therapeutics
- 03 Jul 2023 Phase-I clinical trials in Small cell lung cancer (IV) before June 2023 (Ariceum Therapeutics pipeline, July 2023)
- 03 Jul 2023 Preclinical trials in Merkel cell carcinoma (IV) before June 2023 (Ariceum Therapeutics pipeline, July 2023)